Enterprise Value

135.3M

Cash

15.35M

Avg Qtr Burn

-2.33M

Short % of Float

11.15%

Insider Ownership

12.02%

Institutional Own.

86.75%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Belrapzo (Bendamustine hydrochloride injection) Details
CLL (Chronic Lymphocytic Leukemia) and NHL (non-Hodgkins lymphoma)

Approved

Quarterly sales

Vasopressin Details
Vasodilary shock

Approved

Quarterly sales

Approved

Quarterly sales

Phase 3

Update

Phase 2/3

Data readout

Landiolol Details
Supraventricular tachycardia

Failed

Discontinued